(Q38163014)

English

Metabotropic glutamate receptor 5-negative allosteric modulators for the treatment of psychiatric and neurological disorders (2009-July 2013).

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

30 August 2017

Metabotropic glutamate receptor 5-negative allosteric modulators for the treatment of psychiatric and neurological disorders (2009-July 2013). (English)

1 reference

Europe PubMed Central

30 August 2017

author name string

Guiying Li

1

1 reference

Europe PubMed Central

30 August 2017

Morten Jørgensen

2

1 reference

Europe PubMed Central

30 August 2017

Brian M Campbell

3

1 reference

Europe PubMed Central

30 August 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

1 November 2013

1 reference

Europe PubMed Central

30 August 2017

Pharmaceutical patent analyst

1 reference

Europe PubMed Central

30 August 2017

2

1 reference

Europe PubMed Central

30 August 2017

6

1 reference

Europe PubMed Central

30 August 2017

767-802

1 reference

Europe PubMed Central

30 August 2017

Pharmacological agents acting at subtypes of metabotropic glutamate receptors

1 reference

https://api.crossref.org/works/10.4155%2FPPA.13.58

21 January 2018

Control of calcium oscillations by phosphorylation of metabotropic glutamate receptors

1 reference

https://api.crossref.org/works/10.4155%2FPPA.13.58

21 January 2018

Group I metabotropic glutamate receptor signalling and its implication in neurological disease

1 reference

https://api.crossref.org/works/10.4155%2FPPA.13.58

21 January 2018

Metabotropic glutamate receptors: from the workbench to the bedside

1 reference

https://api.crossref.org/works/10.4155%2FPPA.13.58

21 January 2018

Translational Concepts of mGluR5 in Synaptic Diseases of the Brain

1 reference

https://api.crossref.org/works/10.4155%2FPPA.13.58

21 January 2018

A novel selective metabotropic glutamate receptor 4 agonist reveals new possibilities for developing subtype selective ligands with therapeutic potential

1 reference

https://api.crossref.org/works/10.4155%2FPPA.13.58

21 January 2018

Pharmacological characterization of MRZ-8676, a novel negative allosteric modulator of subtype 5 metabotropic glutamate receptors (mGluR5): focus on L: -DOPA-induced dyskinesia

1 reference

https://api.crossref.org/works/10.4155%2FPPA.13.58

21 January 2018

AFQ056, a new mGluR5 antagonist for treatment of fragile X syndrome

1 reference

https://api.crossref.org/works/10.4155%2FPPA.13.58

21 January 2018

Chronic administration of AFQ056/Mavoglurant restores social behaviour in Fmr1 knockout mice

1 reference

https://api.crossref.org/works/10.4155%2FPPA.13.58

21 January 2018

Chronic pharmacological mGlu5 inhibition corrects fragile X in adult mice.

1 reference

https://api.crossref.org/works/10.4155%2FPPA.13.58

21 January 2018

CTEP: a novel, potent, long-acting, and orally bioavailable metabotropic glutamate receptor 5 inhibitor

1 reference

https://api.crossref.org/works/10.4155%2FPPA.13.58

21 January 2018

Negative allosteric modulation of the mGluR5 receptor reduces repetitive behaviors and rescues social deficits in mouse models of autism

1 reference

https://api.crossref.org/works/10.4155%2FPPA.13.58

21 January 2018

Negative allosteric modulation of metabotropic glutamate receptor 5 results in broad spectrum activity relevant to treatment resistant depression.

1 reference

https://api.crossref.org/works/10.4155%2FPPA.13.58

21 January 2018

mGlu5 negative allosteric modulators: a patent review (2010-2012).

1 reference

https://api.crossref.org/works/10.4155%2FPPA.13.58

21 January 2018

Randomised clinical trial: effects of monotherapy with ADX10059, a mGluR5 inhibitor, on symptoms and reflux events in patients with gastro-oesophageal reflux disease.

1 reference

https://api.crossref.org/works/10.4155%2FPPA.13.58

21 January 2018

Glutamatergic fine tuning with ADX-10059: a novel therapeutic approach for migraine?

1 reference

https://api.crossref.org/works/10.4155%2FPPA.13.58

21 January 2018

Treatment of anxiety using fenobam (a nonbenzodiazepine) in a double-blind standard (diazepam) placebo-controlled study

1 reference

https://api.crossref.org/works/10.4155%2FPPA.13.58

21 January 2018

Epigenetic modification of the FMR1 gene in fragile X syndrome is associated with differential response to the mGluR5 antagonist AFQ056.

1 reference

https://api.crossref.org/works/10.4155%2FPPA.13.58

21 January 2018

A pilot open label, single dose trial of fenobam in adults with fragile X syndrome.

1 reference

https://api.crossref.org/works/10.4155%2FPPA.13.58

21 January 2018

Using the Golden Triangle to optimize clearance and oral absorption

1 reference

https://api.crossref.org/works/10.4155%2FPPA.13.58

21 January 2018

Moving beyond rules: the development of a central nervous system multiparameter optimization (CNS MPO) approach to enable alignment of druglike properties

1 reference

https://api.crossref.org/works/10.4155%2FPPA.13.58

21 January 2018

mGluR5 negative allosteric modulators overview: a medicinal chemistry approach towards a series of novel therapeutic agents

1 reference

https://api.crossref.org/works/10.4155%2FPPA.13.58

21 January 2018

Recent advances in the design and development of novel negative allosteric modulators of mGlu(5)

1 reference

https://api.crossref.org/works/10.4155%2FPPA.13.58

21 January 2018

Nicotinic receptor-mediated enhancement of long-term potentiation involves activation of metabotropic glutamate receptors and ryanodine-sensitive calcium stores in the dentate gyrus.

1 reference

https://api.crossref.org/works/10.4155%2FPPA.13.58

21 January 2018

Discovery, synthesis, and structure-activity relationships of 2-aminoquinazoline derivatives as a novel class of metabotropic glutamate receptor 5 negative allosteric modulators

1 reference

https://api.crossref.org/works/10.4155%2FPPA.13.58

21 January 2018

Discovery and structure-activity relationship of 1,3-cyclohexyl amide derivatives as novel mGluR5 negative allosteric modulators

1 reference

https://api.crossref.org/works/10.4155%2FPPA.13.58

21 January 2018

The identification of novel orally active mGluR5 antagonist GSK2210875.

1 reference

https://api.crossref.org/works/10.4155%2FPPA.13.58

21 January 2018

Discovery of (1R,2R)-N-(4-(6-isopropylpyridin-2-yl)-3-(2-methyl-2H-indazol-5-yl)isothiazol-5-yl)-2-methylcyclopropanecarboxamide, a potent and orally efficacious mGlu5 receptor negative allosteric modulator

1 reference

https://api.crossref.org/works/10.4155%2FPPA.13.58

21 January 2018

Design, synthesis, and structure-activity relationships of novel bicyclic azole-amines as negative allosteric modulators of metabotropic glutamate receptor 5.

1 reference

https://api.crossref.org/works/10.4155%2FPPA.13.58

21 January 2018

The role of aldehyde oxidase and xanthine oxidase in the biotransformation of a novel negative allosteric modulator of metabotropic glutamate receptor subtype 5.

1 reference

https://api.crossref.org/works/10.4155%2FPPA.13.58

21 January 2018

Discovery and characterization of AZD9272 and AZD6538-Two novel mGluR5 negative allosteric modulators selected for clinical development

1 reference

https://api.crossref.org/works/10.4155%2FPPA.13.58

21 January 2018

Identifiers

10.4155/PPA.13.58

1 reference

Europe PubMed Central

30 August 2017

1 reference

Europe PubMed Central

30 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38163014&oldid=1632967002"